72 results about "Embolization Agent" patented technology

An apparatus is provided that is useful in an embolization procedure and enables substantially unrestricted forward flow of blood in a vessel and reduces or stops reflux (regurgitation or backward flow) of embolization agents which are introduced into the blood. A method of using the apparatus is also provided.

The invention relates to a preparation technology for a microspheric embolization agent. The preparation technology is used for preparing elastic microspheres cross-linked and polymerized by functionalized macromolecules with biocompatibility, wherein the grain range of the microspheres is 1-1500mu m. The preparation technology comprises the following steps that: a cross-linkable micromolecule with a crylic acid structure is connected on a polyvinyl alcohol, polyethylene glycol or polyose macromolecule in form of a covalent bond to form a functionalized macromolecule; and reversed phase suspension polymerization is conducted to the functionalized macromolecule and a 2-acrylamide-2-methylpropanesulfonic acid monomer to prepare cross-linked and polymerized microspheric embolization agent. The embolization agent has the advantages that the flexibility and the elasticity are high, the grain is even and is controllable, the dispersity is good, the raw materials are nontoxic and the biocompatibility and the stability are good. The preparation technology is a pure chemical synthesis technology, no virus pollution is caused to the raw materials and the preparation process, the requirements on international embolization agents are satisfied, and the embolization agent can substitute for all kinds of imported or domestic expensive embolization agent products and can be widely used in surgeries in the field of interventional therapy.

The invention provides a pharmaceutical composition for treating embolism and a preparation method thereof, the pharmaceutical composition comprises a hydroxyl-contained biocompatible polymer materialand a monomer containing unsaturated double bonds and anion groups, as well as a polymer generated by polymerization reaction of an optional vinyl monomer, wherein the polymerization is initiated through free radicles, and bleomycin or pingyangmycin is combined on the anion groups of the generated polymer. The preparation method combines the bleomycin or the pingyangmycin on a carrier of the polymer, thereby being capable of fully playing the dual effects of an anti-tumor antibiotic and a hardening agent owned by the bleomycin or the pingyangmycin during the embolism treatment. The anion partof the polymer can be properly combined with the bleomycin or the pingyangmycin which is rich in amino groups, thereby not only realizing the higher drug loading, but also leading the drug in an emboliaztion agent to be exchanged by cation in human body, and further realizing the slow release. In addition, the embolic carrier of the polymer has the advantages of simple prepration technology andlow cost, thereby being applicable to large-scale industrial production.

The invention discloses a novel in situ liquid crystal vascular embolization agent, which mainly comprises a liquid crystal material, a water-soluble physiological acceptable solvent and water, wherein the ratio of mass parts of the liquid crystal material, the water-soluble solvent and the water is 0.3-3.2:1.2-2.1:0.5-1, and the mass percent of the water in the vascular embolization agent is less than 50%; and the liquid crystal material is of an amphiphilic polymer. The in situ liquid crystal vascular embolization agent has the effects of non-toxicity, non-adhesion, easy operation, safety, effectiveness and low cost, and the characteristics of good in vitro fluidity and fast sol-gel conversion speed.

The invention belongs to the technical field of medical polymer materials and in particular relates to X ray developing thermotropic hydrogel and a preparation method thereof. The X ray developing thermotropic hydrogel comprises an iodine-containing amphiphilic block copolymer and a solvent, wherein the iodine-containing amphiphilic block copolymer is obtained by bonding an iodine-containing micromolecule and an amphiphilic block copolymer by virtue of a covalent bond, and thermotropic gelatinization phase transformation can be carried out on a water system of the X ray developing thermotropic hydrogel along with temperature increase. The thermotropic hydrogel can be implanted under the skin and implanted into an abdominal cavity, an articular cavity and other specific parts of a human body in a mode of injection, and in situ formed hydrogel has good X ray developing performance, clear positioning and long-term tracing observation can be carried out on the hydrogel by adopting an X ray radiography technique. The thermotropic hydrogel also can serve as a medicine controlled release carrier, a tissue repairing support, a blood vascular embolization agent, a tissue marker and the like and can be used for realizing integration of diagnosis and treatment.

The invention relates to a carboxymethyl chitosan microsphere embolization agent. The embolization agent takes carboxymethyl chitosan as raw materials; the carboxymethyl chitosan is subjected to pretreatment, emulsification, cross-linking and dehydration drying to prepare microspheres with three-dimensional network structures. After the microspheres absorb water, the microspheres are smooth in surface and are rich in elasticity, have good biocompatibility and biodegradablity and is suitable for non-permanent vascular embolization.

A vascular embolization gelling agent for sustained release of drugs for treating tumors having a drug and a drug carrier. The drugs are antitumor drugs. The drug carrier includes poloxamer polymer and polyvinylpyrrolidone or gel made of the combination, and may be purified before use. The drug carrier accounts for 5-65% of the gel. The particle size of the gel is in the range of 10 nm-150 μm. The embolization agent is a liquid gel at normal temperature, to facilitate direct transcatheter injection, and is rapidly solidified to the gel state in body with the increase of the temperature; it is used to encapsulate different drugs on demand, and can achieve dual efficacy of embolization and drug treatment through local sustained release of the drug. The present invention can be used as the embolization agent for endovascular interventional therapy for transcatheter arterial chemoembolization of various benign and malignant tumors.

The invention relates to a method for preparing a gelatin microballoon embolization agent, which comprises the following steps of dissolving gelatin or mixture of gelatin and medicine at 30-70 DEG C, filtering to obtain gelatin solution with 15%-60% of solid content, adding gelatin solution into oil phase liquid paraffin with mass ratio of 1%-2% of stabilizer Span 80, wherein the volume ratio of water and oil is 1/1-1/10, stirring for 15 minutes by 200-800r/min, adding cross-linking agent aldehyde compound with mass percent of 2%-50% at low temperature of 0-10 DEG C, solidifying for 1-2 hours, washing or drying the cross-linking agent to obtain the microballoon embolization agent after freeze drying or dehydration. The method has the beneficial effects that the gelatin microballoon embolization agent has certain elasticity and expansibility, the surface is smooth, the sphere is obvious, the size and the shape of the sphere is uniform, the grain size is controllable, clinical embolization effect can be improved, and side effect can be lowered, the clinical controllability is strong, antitumor drug can be added into the microballoon in manufacture process, so that double therapeutical effect of medicine treatment and embolization can be realized. The gelatin has good biocompatibility and biodegradablity, and clinical safety can be guaranteed.

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

The invention discloses a preparation method and a use of a liquid embolism agent having drug loading and developing functions. The liquid embolism agent is formed through mixing anion-modified polyethylene-polyvinyl alcohol copolymer (EVOH), a solvent and a developer according to a certain ratio. Negative ion groups are introduced to the high molecular chain of the EVOH through a chemical modification or grafting modification technology, and the negative ion groups can adsorb and load cationized chemotherapeutic anticancer drugs through positive and negative charge interactions. The solvent can be dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP) or ethanol or a mixture of the DMSO, NMP and ethanol. The developer is a metallic tantalum micro-powder or an iodine-containing contrast agent or a mixture of the metallic tantalum micro-powder and the iodine-containing contrast agent. The liquid embolism agent can be widely applied to interventional embolization therapy, and is especiallysuitable for transcatheter arterial chemoembolization (TACE) therapy of liver cancer.

The object of the present invention is to provide an embolizing material which is easily handleable and stable in quality and is solved by providing an embolizing material comprising an ester derivative of a polysaccharide having a weight-average molecular weight of 10,000-500,000 daltons and an average substitution degree of acyl group of over two; an embolizing agent for arteriovenous aneurysm, which comprises the embolizing material and an appropriate physiologically acceptable water-soluble organic acid; and a method of producing an embolizing agent, which comprises a step of dissolving the embolizing material in an appropriate physiologically acceptable water-soluble organic solvent.

A process for preparing the granular embolizing agent from polyvinyl alcohol includes such steps as dissolving polyvinyl formal in aseptic water for injection, freezing at -20--40 deg.C for 10-12 hr, planning on the obtained ice block multiple times to obtain ice particles, classifying by wet sieving by immersing the sieve in suspension to obtain wet polyvinyl formal particles, freezing again, and dry sieving for classifying.

The invention discloses a polyvinyl alcohol nanofiber emboliaztion agent as well as a preparation method and application thereof and belongs to the field of vascular thrombosis materials for interventional therapy. The polyvinyl alcohol nanofiber emboliaztion agent consists of polyvinyl alcohol electrostatic spinning nanofiber granules, wherein the particle sizes of the nanofiber granules is 100-300mu m. The preparation method comprises the following steps: dissolving polyvinyl alcohol granules into water, and heating till the polyvinyl alcohol granules are completely dissolved so as to obtaina polyvinyl alcohol solution of an appropriate concentration as an electrostatic spinning solution; preparing a polyvinyl alcohol nanofiber film from the electrostatic spinning solution by using electrostatic spinning equipment; performing thermal treatment on the nanofiber film; shearing the nanofiber film after thermal treatment, performing low-temperature crushing treatment, and screening, thereby obtaining the polyvinyl alcohol nanofiber granules of which the particle size is 100-300mu m. The emboliaztion agent disclosed by the invention has relatively good treatment effects and biological security, and can be also applied to arterial embolism of various types of malignant tumor such as primary liver cancer and kidney cancer.

The invention discloses the degradable biomaterial microsphere vessel suppository and preparing method. The method comprises the following steps: extracting polysaccharose sodium salt or gelatin from natural agonic acid, using immunocyte factor, such as interleukins-2, tumor necrosis factor and interferon, as presidium, making liposome cytokine micro spheres whose sizes are 50 mum-75 mum, 75 mum-150 mum, 100 mum-200 mum, 200 mum-300 mum, 200 mum-450 mum, 100 mum-300 mum, 300 mum-500 mum, 500 mum-700 mum, and 700 mum-900 mum. The degradable biomaterial microsphere vessel suppository can be used to cure late hepatic carcinoma, kidney cancer, bladder cancer, carcinoma of colon, and other carcinoma arterial embolisms.

The invention relates to temperature controlled thermotherapy embolism sponge particles, which comprise macromolecular material and magnetic responding particles contained therein, the magnetic responding particles made of alloy material having a Curie temperature of 40-65 deg. C are dispersed in a cross-linked network formed by high polymers, the thermotherapy embolism sponge particles have grain diameter of 50-2000um, the water absorption rate is no less than 5 times of the amount of the particles, the magnetic responding particles account to 0.5-45 wt% of the total embolism sponge particles. The invention also discloses the process for preparing the embolism sponge particles.

The invention discloses a developing carboxyl modified polyvinyl alcohol microsphere embolization agent applied to liver cancer tumor embolism. The developing carboxyl modified polyvinyl alcohol microsphere embolization agent disclosed by the invention is characterized by being prepared from three parts of carboxyl modified polyvinyl alcohol, a dispersant and a developing agent according to any proportion. The developing carboxyl modified polyvinyl alcohol microsphere embolization agent has three functions of drug carrying, embolism and developing at the same time. The developing carboxyl modified polyvinyl alcohol microsphere embolization agent can be directly applied to embolism and also can be applied to embolism after medicine carrying; carried medicine is anti-hepatoma medicine; carboxyl modified polyvinyl alcohol polymer is prepared from raw materials of monomer, an initiator and a solvent; the monomer is prepared from vinyl acetate and second comonomer; the second comonomer is one or combination of maleic acid, itaconic acid, pentenedioic acid and itaconic anhydride. By means of continuous polymerization, the carboxyl modified polyvinyl alcohol can be prepared by alcoholysis.

The invention discloses an iodipin and targeted drug compound. The iodipin and targeted drug compound comprises iodipin and a targeted drug, and the targeted drug is targetingly gathered on an in-vivotumor area through the iodipin. The iodipin is adopted as an embolization agent or an area targeting agent, the targeted drug is taken into the tumor area, the targeted drug is targetingly gathered on the tumor area rather than acts on other non-tumor organ tissue, and therefore the side effects of the targeted drug are relieved. Some targeted drugs with an angiogenesis restraining function can restrain angiogenesis caused by inflammatory factor releasing caused by iodipin embolism, and therefore hyperplasia of residual tumor tissue causd by iodipin embolism embolism is restrained.

The invention provides a multifunctional liquid metal embolizing agent as well as a preparation and an application thereof. The multifunctional liquid metal embolizing agent is prepared from liquid metal, functional nanoparticles and a high polymer material, wherein the liquid metal is spherical and forms an inner core of the embolization agent; the functional nanoparticles are dispersed on the surface of the liquid metal; and the high polymer material coates outside the inner core and the functional nanoparticles. The multifunctional liquid metal embolization agent provided by the invention can realize the functions of embolization, CT imaging, MRI imaging, drug loading, thermal conversion, magnetism and the like, and is expected to realize the combination of targeted embolization treatment with chemotherapy, thermal therapy and radiotherapy; and the preparation method of the multifunctional liquid metal microsphere embolization agent provides possibility for more quickly and conveniently preparing the multifunctional microsphere embolization agent with multiple curative effects and diagnosis and treatment integration.

A preparation method of suppository for treating uterine adenomyosis mainly solves the problem of suppository material source and product cost. the preparation method comprises (1) cutting aseptic gelatin sponge into thin slices, overlaying, scissoring one end of the sponge into multiple filaments, scissoring into fine particle until to the other end of the sponge, packaging, sterilizing with oxirane, and standing for 2 weeks; (2) dissolving Pingyangmycin 24 mg in physiological saline for operation; and (3) inserting the conduit into one side of the uterine artery, putting the gelatin sponge into a 20mL disposable syringe, decimating the Pingyangmycin physiological saline solution repeatedly, and injecting with the conduit. The method has the advantages of easily-accessible raw materials, low cost, and high security.

The invention provides an embolic material, and a preparation method and use thereof. The embolic material is prepared from reactant materials; the reactant materials comprise 1 part by weight of sodium alga acid and more than 0.1 part by weight of magnetic metal ions, wherein a coordination compound is formed by the sodium alga acid and the magnetic metal ions. By adopting the embolic material disclosed by the invention, a doctor can directly monitor the position of an embolizing agent by magnetic resonance imaging (MRI) in and after embolization; the curative effect and the safety of embolotherapy are improved.

The invention relates to a developing polylactic acid micro ball vessel suppository, formed by a biological degradable material in polylactic acid and a developing material and baffle the X-ray, wherein, the biological degradable material coats the developing material to form particle structure. The invention has adjustable degrade time; it has better view property in X-ray to support watching plug part; and after plugging, the nuclear magnetic resonance (MRI) can be process; and the invention can suspend in blood, to approach the end blood vessel along with blood, to deposit and plug the vessel; and the diameter of micro ball can be controlled. The invention has low cost.